Biomarker testing is a cornerstone of modern drug development. It enables researchers to assess disease progression and treatment response. We are an innovative Contract Research Organization with over 27 years of expertise in providing accurate and reproducible biomarker analysis to biotechnology companies, pharmaceuticals, and academic researchers.
SBH Sciences provides comprehensive biomarker assay services across multiple platforms that enable us to seamlessly execute complex, high-impact projects that drive scientific advancements. We specialize in ELISA development for the R&D market, multiplex analysis, and automated Western blot technology. SBH supports projects from the initial planning stages to finalizing the study. This includes selecting the biomarker targets and instrumentation to support the project, writing SOPs for all of the work for the project, performing qualifications or validations and optimizing testing conditions, preparing and testing the samples, customizing the analysis, sending data transfers, and providing study reports. SBH optimizes project workflows, provides scientific guidance, and delivers results.
For over a decade, we have delivered end-to-end biomarker and diagnostic development services across the entire therapeutic pipeline:
Early Discovery: Target validation & mechanistic biomarker identification
Lead Optimization: High-throughput PK/PD assay development with MOA alignment
Clinical-Stage Support: CLIA-ready assays for Phase I-III, including companion diagnostic co-development
Our proprietary platform integrates disease biology insights with translational assay refinement, enabling:
→ Early elimination of non-viable candidates through predictive biomarkers
→ Accelerated IND-enabling packages with GLP-compliant validation
→ Seamless transition from exploratory biomarkers to CDx commercialization
Our bioanalytical services have assisted in the development of biotherapeutics based on:
Our collaborative approach enables the highest-quality customizable biomarker services for our clients. We identify the appropriate biomarker, choose the best analytical pathway, develop, quality, and validate the specific assay.
Because your success starts with the perfect fit—not just the latest tech.
In 2024, our scientists provided biomarker analysis and diagnostic support to over 40 companies. SBH Sciences have developed numerous ELISA kits that are commercially available across global vendors. Additionally, SBH Sciences has tested over 300 biomarkers across various multiplex platforms. Our many state-of-the-art platforms allow SBH Sciences to provide the highest quality services to our customers
Our scientists take a collaborative approach when working with our clients to help identify the appropriate biomarker for their research needs. From there we help you choose the ideal instrument to help you develop, optimize, and qualify the specific assay.
SBH Sciences adheres to Good Laboratory Practices (GLP) guidelines, maintaining the integrity and security of all data. We have recently become Certified Service Provider on the Ella instrument. SBH prides itself on delivering rapid and precise biomarker analysis. Assays developed at SBH Sciences can be transferred to our sister company, SBH Diagnostics, a CLIA certified Contract Research Organization. This allows SBH Sciences to support preclinical projects and continue with them when it becomes clinical samples.
